Orthofix Medical’s (OFIX) Buy Rating Reiterated at Roth Mkm

Roth Mkm restated their buy rating on shares of Orthofix Medical (NASDAQ:OFIX) in a research report report published on Wednesday,Benzinga reports. Roth Mkm currently has a $22.00 price target on the medical device company’s stock.

Several other analysts have also commented on OFIX. Stifel Nicolaus upgraded shares of Orthofix Medical from a “hold” rating to a “buy” rating and raised their price objective for the stock from $18.00 to $24.00 in a report on Friday, November 8th. StockNews.com upgraded shares of Orthofix Medical from a “hold” rating to a “buy” rating in a report on Tuesday. Finally, Canaccord Genuity Group initiated coverage on shares of Orthofix Medical in a report on Wednesday, January 22nd. They issued a “buy” rating and a $24.00 price objective for the company. One analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $23.33.

Orthofix Medical Stock Down 1.4 %

NASDAQ OFIX opened at $17.26 on Wednesday. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.39 and a quick ratio of 1.11. The stock has a market capitalization of $659.57 million, a PE ratio of -5.51 and a beta of 1.10. Orthofix Medical has a 1 year low of $12.08 and a 1 year high of $20.73. The business’s 50-day moving average is $17.93 and its 200 day moving average is $17.35.

Insiders Place Their Bets

In other news, CEO Massimo Calafiore sold 10,078 shares of Orthofix Medical stock in a transaction that occurred on Friday, January 10th. The shares were sold at an average price of $16.83, for a total transaction of $169,612.74. Following the completion of the transaction, the chief executive officer now directly owns 133,354 shares in the company, valued at approximately $2,244,347.82. This trade represents a 7.03 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Julie Andrews sold 4,655 shares of Orthofix Medical stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $17.89, for a total transaction of $83,277.95. Following the transaction, the chief financial officer now owns 28,312 shares of the company’s stock, valued at $506,501.68. The trade was a 14.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 25,442 shares of company stock worth $436,883 over the last three months. Company insiders own 2.60% of the company’s stock.

Hedge Funds Weigh In On Orthofix Medical

Several large investors have recently made changes to their positions in OFIX. Juniper Investment Company LLC lifted its holdings in shares of Orthofix Medical by 123.5% during the fourth quarter. Juniper Investment Company LLC now owns 1,937,249 shares of the medical device company’s stock valued at $33,824,000 after purchasing an additional 1,070,656 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in Orthofix Medical by 244.1% in the 4th quarter. JPMorgan Chase & Co. now owns 290,351 shares of the medical device company’s stock worth $5,070,000 after acquiring an additional 205,972 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in Orthofix Medical by 31.8% in the 4th quarter. Dimensional Fund Advisors LP now owns 659,475 shares of the medical device company’s stock worth $11,515,000 after acquiring an additional 159,177 shares during the last quarter. Emerald Mutual Fund Advisers Trust raised its holdings in Orthofix Medical by 35.4% in the 4th quarter. Emerald Mutual Fund Advisers Trust now owns 503,802 shares of the medical device company’s stock worth $8,796,000 after acquiring an additional 131,653 shares during the last quarter. Finally, Boone Capital Management LLC raised its holdings in Orthofix Medical by 13.6% in the 4th quarter. Boone Capital Management LLC now owns 1,057,313 shares of the medical device company’s stock worth $18,461,000 after acquiring an additional 126,806 shares during the last quarter. 89.76% of the stock is currently owned by hedge funds and other institutional investors.

About Orthofix Medical

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.